上海医药：公司持续深入实施中药大品种大品牌战略

Core Viewpoint - The company is actively implementing a strategy focused on major traditional Chinese medicine (TCM) products and brands, leading to steady growth in its TCM segment [1] Group 1: Company Strategy - The company is committed to the deep implementation of a major TCM product and brand strategy [1] - The company has made significant progress in evidence-based medical research for key TCM products such as Wei Fu Chun and Guan Xin Ning [1] Group 2: Mergers and Acquisitions - The successful acquisition of Shanghai He Huang has enabled the company to obtain excellent products like She Xiang Bao Xin Wan and Dan Ning Pian, along with several Class 1 new drugs in development [1] - The acquisition has facilitated synergy in the industrial chain, channel network, and marketing promotion, enhancing the company's TCM business for higher quality development [1]